Phase II Trial of Fulvestrant in Treatment of Recurrent Ovarian Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 09 Nov 2012
At a glance
- Drugs Fulvestrant (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 19 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Oct 2008 Planned end date changed from 1 Apr 2008 to 1 Dec 2008 as reported by ClinicalTrials.gov.